JPMorgan analyst Rachel Vatnsdal assumed coverage of Catalent with a Neutral rating and $45 price target. The analyst maintained the firm’s current rating, price target, and estimates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTLT:
- Catalent put volume heavy and directionally bearish
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug
- Catalent confirms being Regeneron’s Eylea 8 mg third party filler, says Stephens
- Catalent says FDA made three observations in Eylea inspection, Bloomberg reports
- Morgan Stanley says Elevidys label unlikely to have near-term impact on Catalent